Integra Therapeutics is a spin‑out from Pompeu Fabra University (founded in 2020) developing the FiCAT platform, which combines CRISPR‑Cas accuracy with an engineered piggyBac transposase to address payload size, stability, and accuracy limitations in gene therapy. The platform targets applications across genetic, oncological, and autoimmune diseases and is being used to advance next‑generation CAR‑T therapies. The company is also developing a first gene therapy candidate for a rare pediatric liver disease, supported by an EIC Accelerator grant. Integra plans to integrate new advances into FiCAT, expand cell engineering capabilities, and facilitate technology transfer to the pharmaceutical industry. The team intends to use new funding to support preclinical validation of CAR‑T programs and to scale its cell engineering operations. Leadership includes co‑founders Dr. Marc Güell and Dr. Avencia Sánchez‑Mejías; the company is based in Barcelona. Integra Therapeutics is a Barcelona‑based biotech spin‑off (founded 2020 from Pompeu Fabra University) developing FiCAT, a gene‑writing platform intended to overcome current limits on size, precision and stability. Its core product, FiCAT, targets ex vivo engineering of T cells and hematopoietic stem cells and systemic in vivo gene therapy using non‑viral lipid nanoparticle (LNP) delivery. The company plans to use initial funding to support pre‑marketing activities for cell therapy applications across rare diseases, autoimmune disorders and oncology. In parallel, Integra will generate proof‑of‑concept data for a first gene therapy aimed at a serious pediatric hepatic disease using systemic non‑viral delivery. Longer term, Integra intends to expand FiCAT to extra‑hepatic indications and to pursue licensing and co‑development partnerships to broaden patient access. The company is led by co‑founders Dr Marc Güell and Dr Avencia Sánchez‑Mejías. Integra Therapeutics develops next-generation gene writing tools and is advancing a gene writing platform called FiCAT to improve safety and efficacy of advanced therapies. The company targets prevention and treatment of genetic diseases and cancers with unmet medical needs. Co-founded by Marc Güell and Avencia Sánchez-Mejías, Integra is working toward a FiCAT platform prototype and preclinical validation. The planned preclinical work includes in vivo and ex vivo models. Financially, the company raised an additional €1.5m in seed funding in March 2022 following a €4.5m seed raise in December. The new investment includes participation from Columbus Venture Partners, which will place a representative on the board. Integra Therapeutics (Integra Tx) is a biotechnology spin-off from Pompeu Fabra University focused on creating next-generation gene writing tools to make advanced therapies safer and more effective. The company was founded in late 2020 based on technology developed in the Translational Synthetic Biology Lab led by Dr. Marc Güell and Avencia Sánchez-Mejías. Integra intends to complete a prototype of its gene writing platform and carry out preclinical validation using in vivo and ex vivo models. It plans to manage and expand its patent portfolio through 2022 and 2023. The company raised €4.5M in its first round of funding to support these development activities. After prototyping and preclinical work, Integra plans to open a Series A to seek regulatory approval and carry out clinical trials with patients.

Total raised

$31M

Funding rounds

5

Latest round

Series A

Latest activity

Sep 2025